Ignite Creation Date:
2024-05-06 @ 12:04 PM
Last Modification Date:
2024-10-26 @ 12:54 PM
Study NCT ID:
NCT03672097
Status:
COMPLETED
Last Update Posted:
2021-11-12
First Post:
2018-09-13
Brief Title:
Prasugrel Switching Study in Patients With Acute Coronary Syndrome ACS Who Underwent Percutaneous Coronary Intervention PCI
Sponsor:
Daiichi Sankyo Taiwan Ltd a Daiichi Sankyo Company
Organization:
Daiichi Sankyo
Study Overview
Official Title:
Phase IV Non-comparative Open Label Multicenter 28-Week Switching Study of Prasugrel Maintenance Dose From Clopidogrel in Patients With Acute Coronary Syndrome ACS Who Underwent a Percutaneous Coronary Intervention PCI in Taiwan
Status:
COMPLETED
Status Verified Date:
2021-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This Phase IV multicenter trial is designed to assess the efficacy of prasugrel in preventing the formation of blood clots in Taiwanese patients with ACS who have been treated with PCI
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None